TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7017485

Group type: EXPERIMENTAL
Intervention: guacetisal
Number of subjects: 30

Group type: COMPARATOR
Intervention: oxolamine phosphate
Number of subjects: 30
Study: 31083704

Group type: EXPERIMENTAL
Intervention: AW group (18% oral carbohydrate solution)
Number of subjects: 34

Group type: COMPARATOR
Intervention: PW group (plain water)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 28012183

Group type: EXPERIMENTAL
Intervention: Eczema Area and Severity Index (EASI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: objective Scoring Atopic Dermatitis (oSCORAD)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Investigator's Global Assessment (IGA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Novel greyscale
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All scoring measures
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Erythema component analysis
Number of subjects: 25
Study: 25873139

Group type: EXPERIMENTAL
Intervention: Grocery store-based dietary counselling
Number of subjects: 55

Group type: COMPARATOR
Intervention: Clinic-based dietary counselling
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 23528626

Group type: EXPERIMENTAL
Intervention: mesalamine (Asacol 800‐mg tablet) 4.8 g/day
Number of subjects: 281

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: mesalamine (Asacol 800‐mg tablet) 4.8 g/day after excluding ineligible patients
Number of subjects: 281

Group type: COMPARATOR
Intervention: placebo after excluding ineligible patients
Number of subjects: 281
Study: 21059830

Group type: EXPERIMENTAL
Intervention: SBP ≥140 mmHg at baseline
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: SBP ≥140 mmHg On-Study
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: DBP <70 mmHg at baseline
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: DBP <70 mmHg On-Study
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: SBP ≥140 with DBP <70 mmHg at baseline
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: SBP ≥140 with DBP <70 mmHg On-Study
Number of subjects: 1791
Study: 19344437

Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Oral ganciclovir (3000 mg/day)
Number of subjects: 76
Study: 17708626

Group type: EXPERIMENTAL
Intervention: Taiji and Qigong (TQ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 50
Study: 15008318

Group type: EXPERIMENTAL
Intervention: Active warming with a carbon-fiber heating blanket set to 42 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive warming with a carbon-fiber heating blanket switched off
Number of subjects: 30
Study: 11683187

Group type: EXPERIMENTAL
Intervention: Incubator cover
Number of subjects: 9

Group type: COMPARATOR
Intervention: No incubator cover
Number of subjects: 9
Study: 9743397

Group type: EXPERIMENTAL
Intervention: Antihistamines (1 mg/kg diphenhydramine and 4 mg/kg cimetidine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8048862

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (cholecystolithiasis only)
Number of subjects: 186
Study: 2563688

Group type: EXPERIMENTAL
Intervention: Benorylate 4 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30696465

Group type: EXPERIMENTAL
Intervention: Blended-learning training (e-learning + skills-training workshop)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Information leaflet about reputable websites
Number of subjects: 480
Study: 28166784

Group type: EXPERIMENTAL
Intervention: CCM-based intervention with APC-CHW team including a minimum of three clinic visits, three home visits, and Chronic Disease Self-Management Program group workshops
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: CCM-based intervention with APC-CHW team
Number of subjects: 516
Study: 25733462

Group type: COMPARATOR
Intervention: High-protein preload (PRO; 29 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-calcium preload (CAL; 1170 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-protein and high-calcium preload (PROCAL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-calcium and low-protein control preload (CON)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-protein preload (PRO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-calcium preload (CAL)
Number of subjects: 20
Study: 23203707

Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost (T2345)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BAK-preserved latanoprost (BPL)
Number of subjects: 0
Study: 21386896

Group type: EXPERIMENTAL
Intervention: Salient distractor (high contrast)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target (low contrast)
Number of subjects: 0
Study: 18191090

Group type: EXPERIMENTAL
Intervention: Blue light-filter intraocular lenses (yellow IOL group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ultraviolet-filter intraocular lenses (clear IOL group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both IOL groups
Number of subjects: 60
Study: 16780997

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2b (1.5 microg/kg/week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: peginterferon alfa‐2a (180 microg/week)
Number of subjects: 36
Study: 14644515

Group type: EXPERIMENTAL
Intervention: Central arm (rapid diagnostic system)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional arm (local investigation)
Number of subjects: 88
Study: 11025704

Group type: EXPERIMENTAL
Intervention: Medical therapy for benign prostatic hyperplasia
Number of subjects: 0
Study: 8775354

Group type: EXPERIMENTAL
Intervention: Low intensity training (50% of VO2max)
Number of subjects: 197

Group type: COMPARATOR
Intervention: High intensity training (85% of VO2max)
Number of subjects: 197
Study: 1457115

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 570 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 710 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ORG 9426 at 850 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ORG 9426 (all doses)
Number of subjects: 36
Study: 6233348

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (n = 24)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (n = 24)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus pharmacotherapy (n = 22)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus active placebo (n = 17)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Single treatment modalities
Number of subjects: 87
Study: 30654370

Group type: EXPERIMENTAL
Intervention: Iso osmolar medium (IOCM)
Number of subjects: 146

Group type: COMPARATOR
Intervention: High osmolality contrast medium (HOCM)
Number of subjects: 146
Study: 29424680

Group type: EXPERIMENTAL
Intervention: Web-based intervention with personalized normative feedback screen
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1057
Study: 26825365

Group type: EXPERIMENTAL
Intervention: Clopacin(®) 75 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference drug (originator)
Number of subjects: 48
Study: 24952740

Group type: EXPERIMENTAL
Intervention: Practice network-based care management intervention (three home visits, 24 structured telephone monitoring contacts, self-monitoring of blood glucose levels after T1 in 3-month intervals)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Practice network-based care management intervention
Number of subjects: 582

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 582
Study: 23054063

Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg + Caffeine 130 mg (PCF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg (SUM)
Number of subjects: 0
Study: 20735782

Group type: EXPERIMENTAL
Intervention: Synbiotic comprising Bifidobacterium longum and Synergy 1
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18370567

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: No HMG-CoA reductase inhibitor (statin) therapy
Number of subjects: 0
Study: 16319510

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GMC) 1,200 mg/m² on days 1 and 8, Cisplatin (CDDP) 75 mg/m² on day 2, repeated every 21 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GMC) and Cisplatin (CDDP) regimen
Number of subjects: 27
Study: 11752997

Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine (2 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 65
Study: 10079447

Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: flurbiprofen
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: prednisolone acetate
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 7484027

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suxamethonium 1 mg kg‐1 without prior atracurium or anticholinesterase administration
Number of subjects: 30
Study: 2387660

Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 6113021

Group type: EXPERIMENTAL
Intervention: 3 g sulphasalazine retention enemas
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo retention enemas
Number of subjects: 34
Study: 31936621

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 140 mL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 31683114

Group type: EXPERIMENTAL
Intervention: Psychological First Aid training (60 min sessions, once a week for 6 weeks)
Number of subjects: 76
Study: 27942868

Group type: EXPERIMENTAL
Intervention: Experimental Music Therapy Group (EMG)
Number of subjects: 100
Study: 25979840

Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isotonic contractions
Number of subjects: 6
Study: 23274144

Group type: EXPERIMENTAL
Intervention: FDC capsule containing lamivudine/adefovir dipivoxil 100/10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional lamivudine 100 mg + adefovir dipivoxil 10 mg tablets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments (FDC and conventional tablets)
Number of subjects: 40
Study: 21113613

Group type: EXPERIMENTAL
Intervention: Poling frequency of 40 cycles·min(‐1) (Pf(40))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Poling frequency of 60 cycles·min(‐1) (Pf(60))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Poling frequency of 80 cycles·min(‐1) (Pf(80))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison of Pf(40), Pf(60), and Pf(80)
Number of subjects: 9
Study: 22642735

Group type: EXPERIMENTAL
Intervention: Home-based treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hospital-based treatment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 29
Study: 16817045

Group type: EXPERIMENTAL
Intervention: Initial medical treatment
Number of subjects: 139
Study: 12753488

Group type: EXPERIMENTAL
Intervention: Heavy training group (HT, n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 17
Study: 10680924

Group type: EXPERIMENTAL
Intervention: Saline irrigation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Otic drops
Number of subjects: 62
Study: 9058223

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride 0.2 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (both doses)
Number of subjects: 20
Study: 8342319

Group type: EXPERIMENTAL
Intervention: Bivalent cold recombinant type A (CRA) vaccines
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza (TI) vaccines
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline by nose drops (Pli.n.)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline intramuscularly (Pli.m.)
Number of subjects: 52
Study: 3578940

Group type: EXPERIMENTAL
Intervention: Autologous transfusion (group II)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 29661635

Group type: EXPERIMENTAL
Intervention: Intervention group receiving intermittent preventive treatment (IPT) with dihydroartemisinin-piperaquine (DP)
Number of subjects: 10079

Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 10079

Group type: EXPERIMENTAL
Intervention: Intervention group receiving IPT with DP
Number of subjects: 10079
Study: 28071624

Group type: EXPERIMENTAL
Intervention: Accelerated RT (six fractions per week, Monday-Saturday)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional RT (five fractions per week, Monday-Friday)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Accelerated RT and Conventional RT)
Number of subjects: 60
Study: 24702445

Group type: EXPERIMENTAL
Intervention: o/w formulation containing licochalcone A, decanediol, menthoxypropanediol and ω‐6‐fatty acids (emollient arm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1% hydrocortisone (HC arm)
Number of subjects: 20
Study: 23984793

Group type: EXPERIMENTAL
Intervention: Exenatide + Metformin
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo + Metformin
Number of subjects: 174
Study: 20530557

Group type: EXPERIMENTAL
Intervention: Manual therapy and home exercise programme
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo treatment (inactive ultrasound therapy and inert gel)
Number of subjects: 120
Study: 18206891

Group type: EXPERIMENTAL
Intervention: Hcy-lowering agents (folate 1000 mcg, vitamin B12 400 mcg, vitamin B6 10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16447306

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program (6-month group-based)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Educational Support Program (group-based)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard Care Program (no group)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 134
Study: 15531493

Group type: COMPARATOR
Intervention: 10 x 250 mg T enanthate (TE) im every 3 wk (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 x 1000 mg TU im every 6 wk (loading dose) followed by 1 x 1000 mg after an additional 9 wk (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8 x 1000 mg TU every 12 wk in former TU patients (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 x 1000 mg TU every 8 wk plus 6 x 1000 mg every 12 wk in former TE patients (n = 16)
Number of subjects: 40
Study: 11570643

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no DEX treatment)
Number of subjects: 40
Study: 9663150

Group type: EXPERIMENTAL
Intervention: Work-site wellness-health program interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (workers from two other sites)
Number of subjects: 0
Study: 8173679

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study: 3223457

Group type: EXPERIMENTAL
Intervention: 6,000 micrograms/day mecobalamin
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 1,500 micrograms/day mecobalamin
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 29413802

Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback during rehabilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no biofeedback)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Real-time visual biofeedback
Number of subjects: 24
Study: 28269765

Group type: EXPERIMENTAL
Intervention: Bapineuzumab IV
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2452
Study: 25658816

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 18
Study: 23484826

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 283

Group type: COMPARATOR
Intervention: Prolonged conservative care
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Disk herniation visible
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: No disk herniation
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Disk herniation
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: MRI assessment
Number of subjects: 283
Study: 21419556

Group type: EXPERIMENTAL
Intervention: SNIP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PImax
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pes (reference variable)
Number of subjects: 52
Study: 18815989

Group type: EXPERIMENTAL
Intervention: Group-administered interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16946607

Group type: EXPERIMENTAL
Intervention: Chewing gums (1.3 g xylitol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sucking tablets (0.8 g xylitol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candy tablets (1.1 g xylitol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Toothpaste (0.1 g xylitol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rinse (1.0 g xylitol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LX rinse (2.0 g xylitol)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HX rinse (6.0 g xylitol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (non‐xylitol paraffin)
Number of subjects: 12
Study: 14512708

Group type: EXPERIMENTAL
Intervention: Cocaine abusers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 11195958

Group type: EXPERIMENTAL
Intervention: Vacuum extractor
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 9187688

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 4222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4222
Study: 8416021

Group type: EXPERIMENTAL
Intervention: Intranasal arginine vasopressin (20 IU)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (20 IU)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3753116

Group type: EXPERIMENTAL
Intervention: CPR training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Risk factor education
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 29247670

Group type: EXPERIMENTAL
Intervention: High heat capacity mattress (HHCM)
Number of subjects: 15
Study: 27508910

Group type: EXPERIMENTAL
Intervention: Acupressure on the sanyinjiao point for 20 minutes during contractions
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 24287402

Group type: EXPERIMENTAL
Intervention: Recruitment via GPs (N = 144)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Recruitment via newspapers (N = 213)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Recruitment via GPs
Number of subjects: 832
Study: 22933207

Group type: EXPERIMENTAL
Intervention: Trial treatment (TT)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Routine thrombolytic treatment (Thrx)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Trial treatment (TT) subgroup (refused participation)
Number of subjects: 189
Study: 20424804

Group type: EXPERIMENTAL
Intervention: Supplement intervention (oral liquid nutrition supplementation)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Between-meal snacks intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual NH care control
Number of subjects: 63
Study: 18519918

Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg qd for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: carbamazepine titrated to 400 mg qd for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration of carbamazepine with efavirenz
Number of subjects: 0
Study: 15988694

Group type: EXPERIMENTAL
Intervention: Diet alone (D)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Exercise alone (EX)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diet + Exercise (D + E)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 33
Study: 12550149

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10539093

Group type: EXPERIMENTAL
Intervention: Herbal immunomodulator (Esberitox N)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8905957

Group type: EXPERIMENTAL
Intervention: Medium sized probe
Number of subjects: 6

Group type: COMPARATOR
Intervention: Adult type probe
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both probes
Number of subjects: 6
Study: 1660530

Group type: EXPERIMENTAL
Intervention: Oat bran (28 g [1 oz] twice daily)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Wheat cereal
Number of subjects: 145

Group type: COMPARATOR
Intervention: Diet alone (AHA-I diet)
Number of subjects: 145
Study: 10328017

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ; 80 mg of TMP and 400 mg of SMZ per tablet; nine tablets taken once daily for three days; total, 27 tablets)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Tetracycline (2 g daily for five days)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 938